02:53 PM EST, 01/28/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the US Food and Drug Administration approved its Ozempic to reduce the risk of kidney failure, worsening kidney disease and death due to cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease. Price: 86.01, Change: -1.50, Percent Change: -1.71 ...

Benchmark analyst Cody Acree named Tower Semiconductor ( TSEM ) Inc. among recommended oversold names following Monday’s market rout, which was triggered by DeepSeek’s announcement of its advanced language model. Monday’s Selloff: Chinese AI lab DeepSeek unveiled a new large language model reportedly meeting or exceeding leading competitors’ performance at a fraction of the cost. The claims, though met with...

Jan 28 (Reuters) - QMSK Technology Co Ltd: * QMSK TECHNOLOGY CO LTD: FILES FOR U.S. IPO * QMSK TECHNOLOGY CO., LTD: EXPECT IPO OFFERING PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE * QMSK TECHNOLOGY CO: EXPECT US IPO PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE...

Jan 28 (Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes. Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same...